Overview

Study to Characterize the Pharmacokinetics of 3 Marketed Products Containing 200 mg Guaifenesin in Healthy Volunteers.

Status:
Completed
Trial end date:
2009-07-16
Target enrollment:
Participant gender:
Summary
Characterize the relative pharmacokinetics (PK) of 3 marketed products containing guaifenesin
Phase:
Phase 1
Details
Lead Sponsor:
Reckitt Benckiser Inc.
Treatments:
Chlorpheniramine, phenylpropanolamine drug combination
Guaifenesin
Phenylpropanolamine